Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	244	3q13.31	TIGIT	T cell immunoreceptor with Ig and ITIM domains	5
Mouse	1	249	16 B4	Tigit	T cell immunoreceptor with Ig and ITIM domains
Rat	-	-	11q21	Tigit	T cell immunoreceptor with Ig and ITIM domains

Previous and Unofficial Names

T-cell immunoreceptor with Ig and ITIM domains | V-set and immunoglobulin domain containing 9 | V-set and transmembrane domain containing 3 | VSIG9 | VSTM3 | WUCAM [2]

Database Links
Alphafold	Q495A1 (Hs), P86176 (Mm)
CATH/Gene3D	2.60.40.10
ChEMBL Target	CHEMBL4630878 (Hs)
Ensembl Gene	ENSG00000181847 (Hs), ENSMUSG00000071552 (Mm), ENSRNOG00000056574 (Rn)
Entrez Gene	201633 (Hs), 100043314 (Mm), 363784 (Rn)
Human Protein Atlas	ENSG00000181847 (Hs)
KEGG Gene	hsa:201633 (Hs), mmu:100043314 (Mm), rno:363784 (Rn)
OMIM	612859 (Hs)
Pharos	Q495A1 (Hs)
RefSeq Nucleotide	NM_173799 (Hs), NM_001146325 (Mm)
RefSeq Protein	NP_776160 (Hs), NP_001139797 (Mm)
UniProtKB	Q495A1 (Hs), P86176 (Mm)
Wikipedia	TIGIT (Hs)

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols		Click column headers to sort
Antibody Sp. Action Value Parameter Reference domvanalimab Hs Binding - - 1 ⤷ [1] etigilimab Hs Binding - - 4 ⤷ [4]

Immunopharmacology Comments

TIGIT is now considered as an alternate inhibitory immune checkpoint protein which may have potential immunotherapeutic potential, particularly in conditions refractory to more established PD-1 checkpoint inhibition. Given its presence on T cells and NK cells, TIGIT offers an intervention point for targeting both the adaptive and innate arms of the immune system. Clinical development of anti-TIGIT monoclonal antibodies is in preliminary stages. Combination therapies with existing immune checkpoint inhibitors are considered particularly promising. MTIG7192A (NCT02794571; ± anti-PD-L1 atezolizumab) and BMS-986207 (NCT02913313; ± anti-PD-1 nivolumab) are two early phase potential immuno-oncology mAbs that prevent TIGIT-PVR interaction. OncoMed, Arcus Biosciences and Merck also have anti-TIGIT antibodies in their immuno-oncology pipelines (OMP-313M32/etigilimab, AB154/domvanalimab, and MK-7684 respectively) [4].

Cell Type Associations

Immuno Cell Type:  Innate lymphoid cells Cell Ontology Term:   group 1 innate lymphoid cell (CL:0001067) group 3 innate lymphoid cell (CL:0001071) Comment:  TIGIT is expressed by human ILC1s and ILC3s. References:  3

Immuno Cell Type:  Natural killer cells References:  3,5

Immuno Cell Type:  T cells Comment:  Expressed on regulatory, memory and activated T cells. References:  5

General Comments

TIGIT was originally identified as a high affinity binding partner of the poliovirus receptor (PVR; P15151). TIGIT-PVR interaction promotes the generation of mature immunoregulatory dendritic cells and leads to suppression of T cell activation. The TIGIT protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590.